Chembio Diagnostics, Inc. (NASDAQ: CEMI), relating to its proposed sale to Biosynex SA. Under the terms of the agreement, CEMI shareholders are expected to receive $0.45 in cash per share they own.
Chembio Diagnostics, Inc. (NASDAQ: CEMI), relating to its proposed sale to Biosynex SA. Under the terms of the agreement, CEMI shareholders are expected to receive $0.45 in cash per share they own.